Jim Cramer on Catalyst Pharmaceuticals: "It's a Very Inexpensive Stock"

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the stocks on Jim Cramer’s radar recently. During the lightning round, a caller asked if they should buy more, hold, or sell their position in the stock, and here’s what Cramer had to say in response:

“I like Catalyst Pharmaceuticals. It actually has, by the way, real earnings, and it’s a very inexpensive stock. I think you’ve got a winner.”

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) provides treatments for patients managing rare conditions such as Lambert-Eaton myasthenic syndrome and Duchenne muscular dystrophy. During the episode that aired on March 25, 2025, a caller inquired about the stock and Cramer replied:

“No, I think it’s very good and it’s had a very good year. It’s up more than almost every other drug, any company I follow. Yeah, we did like it. Now remember this [is] still [a] small cap stock and there’s some insider selling, but I do think it’s just a very good situation. We went over that a while ago and it beat the earnings estimates…. They were supposed to earn 55 cents and earned 70 cents. That’s my kind of stock. I think you’re in good shape.”

It should be noted that since the above comment was aired, Catalyst Pharmaceuticals, Inc.’s (NASDAQ:CPRX) stock has declined by around 13%.

While we acknowledge the potential of CPRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.